B cell responses and antibody‐based therapeutic perspectives in human cancers
Abstract Background Immuno‐oncology has been focused on T cell‐centric approaches until the field recently started appreciating the importance of tumor‐reactive antibody production by tumor‐infiltrating plasma B cells, and the necessity of developing novel therapeutic antibodies for the treatment of...
| Main Authors: | , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2024-03-01
|
| Series: | Cancer Reports |
| Subjects: | |
| Online Access: | https://doi.org/10.1002/cnr2.2056 |
| _version_ | 1797236860181807104 |
|---|---|
| author | Gunjan Mandal Suchismita Pradhan |
| author_facet | Gunjan Mandal Suchismita Pradhan |
| author_sort | Gunjan Mandal |
| collection | DOAJ |
| description | Abstract Background Immuno‐oncology has been focused on T cell‐centric approaches until the field recently started appreciating the importance of tumor‐reactive antibody production by tumor‐infiltrating plasma B cells, and the necessity of developing novel therapeutic antibodies for the treatment of different cancers. Recent Findings B lymphocytes often infiltrate solid tumors and the extent of B cell infiltration normally correlates with stronger T cell responses while generating humoral responses against malignant progression by producing tumor antigens‐reactive antibodies that bind and coat the tumor cells and promote cytotoxic effector mechanisms, reiterating the fact that the adaptive immune system works by coordinated humoral and cellular immune responses. Isotypes, magnitude, and the effector functions of antibodies produced by the B cells within the tumor environment differ among cancer types. Interestingly, apart from binding with specific tumor antigens, antibodies produced by tumor‐infiltrating B cells could bind to some non‐specific receptors, peculiarly expressed by cancer cells. Antibody‐based immunotherapies have revolutionized the modalities of cancer treatment across the world but are still limited against hematological malignancies and a few types of solid tumor cancers with a restricted number of targets, which necessitates the expansion of the field to have newer effective targeted antibody therapeutics. Conclusion Here, we discuss about recent understanding of the protective spontaneous antitumor humoral responses in human cancers, with an emphasis on the advancement and future perspectives of antibody‐based immunotherapies in cancer. |
| first_indexed | 2024-04-24T17:10:34Z |
| format | Article |
| id | doaj.art-6d9fe2092f444537aa6d7290fdba2f9c |
| institution | Directory Open Access Journal |
| issn | 2573-8348 |
| language | English |
| last_indexed | 2024-04-24T17:10:34Z |
| publishDate | 2024-03-01 |
| publisher | Wiley |
| record_format | Article |
| series | Cancer Reports |
| spelling | doaj.art-6d9fe2092f444537aa6d7290fdba2f9c2024-03-28T12:30:35ZengWileyCancer Reports2573-83482024-03-0173n/an/a10.1002/cnr2.2056B cell responses and antibody‐based therapeutic perspectives in human cancersGunjan Mandal0Suchismita Pradhan1Division of Cancer Biology DBT‐Institute of Life Sciences Bhubaneswar IndiaDivision of Cancer Biology DBT‐Institute of Life Sciences Bhubaneswar IndiaAbstract Background Immuno‐oncology has been focused on T cell‐centric approaches until the field recently started appreciating the importance of tumor‐reactive antibody production by tumor‐infiltrating plasma B cells, and the necessity of developing novel therapeutic antibodies for the treatment of different cancers. Recent Findings B lymphocytes often infiltrate solid tumors and the extent of B cell infiltration normally correlates with stronger T cell responses while generating humoral responses against malignant progression by producing tumor antigens‐reactive antibodies that bind and coat the tumor cells and promote cytotoxic effector mechanisms, reiterating the fact that the adaptive immune system works by coordinated humoral and cellular immune responses. Isotypes, magnitude, and the effector functions of antibodies produced by the B cells within the tumor environment differ among cancer types. Interestingly, apart from binding with specific tumor antigens, antibodies produced by tumor‐infiltrating B cells could bind to some non‐specific receptors, peculiarly expressed by cancer cells. Antibody‐based immunotherapies have revolutionized the modalities of cancer treatment across the world but are still limited against hematological malignancies and a few types of solid tumor cancers with a restricted number of targets, which necessitates the expansion of the field to have newer effective targeted antibody therapeutics. Conclusion Here, we discuss about recent understanding of the protective spontaneous antitumor humoral responses in human cancers, with an emphasis on the advancement and future perspectives of antibody‐based immunotherapies in cancer.https://doi.org/10.1002/cnr2.2056antibody‐based immunotherapiesimmunoglobulin class‐switchingtumor microenvironmenttumor‐infiltrating B lymphocytes |
| spellingShingle | Gunjan Mandal Suchismita Pradhan B cell responses and antibody‐based therapeutic perspectives in human cancers Cancer Reports antibody‐based immunotherapies immunoglobulin class‐switching tumor microenvironment tumor‐infiltrating B lymphocytes |
| title | B cell responses and antibody‐based therapeutic perspectives in human cancers |
| title_full | B cell responses and antibody‐based therapeutic perspectives in human cancers |
| title_fullStr | B cell responses and antibody‐based therapeutic perspectives in human cancers |
| title_full_unstemmed | B cell responses and antibody‐based therapeutic perspectives in human cancers |
| title_short | B cell responses and antibody‐based therapeutic perspectives in human cancers |
| title_sort | b cell responses and antibody based therapeutic perspectives in human cancers |
| topic | antibody‐based immunotherapies immunoglobulin class‐switching tumor microenvironment tumor‐infiltrating B lymphocytes |
| url | https://doi.org/10.1002/cnr2.2056 |
| work_keys_str_mv | AT gunjanmandal bcellresponsesandantibodybasedtherapeuticperspectivesinhumancancers AT suchismitapradhan bcellresponsesandantibodybasedtherapeuticperspectivesinhumancancers |